Lantheus Gets FDA CRL for LNTH-2501; No Safety or Efficacy Concerns Raised
The delay is due to manufacturing issues at a third-party facility, with no safety or clinical data concerns.
/ 3 items
#LNTH↓
Curium Makes $7 Billion Takeover Offer for Lantheus Holdings
Lantheus is in talks to be bought by Curium for about $7B. No deal yet. Stock rose. Deal would be big in nuclear medicine.
New Partnership Brings Leading Prostate Cancer Detection Tool to Japan
Lantheus licenses PYLARIFY, a leading PSMA PET imaging agent for prostate cancer, exclusively to GE HealthCare for development, manufacturing, and sales in Japan, a key international market.